Komori
Medinet (2370) · InitiativeAdvancedLatest Earnings (2026-08-13): "Achieved"

Deficit Offset Through Capital Reduction Without Compensation and Transfer of Surplus

First written in FY2017-Q1. 7 of 10 entries say "Achieved", first in FY2017-Q1. Latest entry: 2026-08-13.

10entries
10years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017AchievedFY2021-Q1 – 2026-08-132017: 220172018: 020182019: 020192020: 020202021: 120212022: 120222023: 120232024: 020242025: 220252026: 32026
Same theme, other companies
Capital Policy and Dividend Preparation through Capital Reduction and Deficit EliminationA theme 289 companies write about · 1 as a headwind · 288 as a tailwind

127 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 291 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025AdvancedAnnual report

    「At the 30th Annual General Meeting of Shareholders held on 17 December 2025, the company resolved to reduce its stated capital and capital reserve and dispose of surplus, with 31 January 2026 as the effective date.」

    As a new deficit offset, the company resolved to reduce stated capital by ¥1,358,288,102 and capital reserve by ¥3,850,056, and transfer ¥1,362,138,158 of other capital surplus to retained earnings brought forward. The effective date is scheduled for 31 January 2026.
  2. FY2025-H1AchievedAnnual report

    「Based on a resolution of the 29th Annual General Meeting of Shareholders held on 18 December 2024, the company offset the deficit in retained earnings brought forward as of 31 January 2025.」

    As of 31 January 2025, the company completed the deficit offset by reducing stated capital by ¥1,387.762 million and capital reserve by ¥1,327.182 million and transferring the amounts to retained earnings.
  3. FY2023-Q1AchievedAnnual report

    「At the 27th Annual General Meeting of Shareholders held on 15 December 2022, the company resolved to reduce its stated capital and capital reserve and dispose of surplus, and the resolution took effect on 31 January 2023.」

    The company reduced its stated capital of ¥733,040,168 and capital reserve of ¥1,360,593,200 without compensation, and transferred the entire ¥2,093,633,368 of other capital surplus to retained earnings brought forward, completing the deficit offset.
  4. FY2022AdvancedAnnual report

    「At the 27th Annual General Meeting of Shareholders held on 15 December 2022, the company resolved to reduce its stated capital and capital reserve and dispose of surplus.」

    On 15 December 2022, the company resolved to reduce stated capital by ¥733.040 million and capital reserve by ¥1,360.593 million, and transfer ¥2,093.633 million of other capital surplus to retained earnings brought forward to offset the deficit. The effective date was scheduled for 31 January 2023.
  5. FY2021-Q1AchievedAnnual report

    「The change took effect on 31 January 2021.」

    The company reduced its stated capital of ¥4,318,250,198 and capital reserve of ¥3,034,207,425 without compensation, and transferred the entire amount of other capital surplus to retained earnings brought forward to offset the deficit.
  6. FY2017RestatedAnnual report

    「As a result of offsetting the deficit in retained earnings brought forward pursuant to a resolution of the shareholders meeting, stated capital decreased by ¥963.123 million, capital surplus decreased by ¥8,191.153 million, and retained earnings increased by ¥9,154.276 million,」

    The deficit offset through the capital reduction without compensation, reduction of capital reserve and transfer of surplus was also confirmed in the financial statements.
  7. FY2017-Q1AchievedAnnual report

    「To eliminate the deficit in retained earnings and strengthen our financial position, we decided to reduce the amounts of share capital and capital reserve under Article 447, Paragraph 1 and Article 448, Paragraph 1 of the Companies Act and dispose of surplus under Article 452 of the Companies Act. Share capital of ¥6,778,593,475 was reduced by ¥963,123,061 to ¥5,815,470,414. Capital reserve of ¥8,191,153,475 was reduced in full, leaving capital reserve at ¥0.」

    A capital reduction without consideration and a disposal of surplus became effective on 31 January 2017. Share capital and capital reserve were reduced, and other capital surplus was transferred to retained earnings to eliminate the deficit.
Moved together

"Commercialization of the Contract Cell-Processing Business" moved the same way as this thread, in the same document, in 6 of its 10 moves.

665433★123456
  1. ★This thread
  2. 1Commercialization of the Contract Cell-Processing Business6×
  3. 2Financing Through Third-Party Allotments, Convertible Bonds and Stock Acquisition Rights6×
  4. 3Revenue Growth Including Income from New Businesses5×
  5. 4Commercialization of the Regenerative and Cell Medicine Value Chain4×
  6. 5Contract Manufacturing of S-DSC® Using Technology Provided by Shiseido Company,Limited3×
  7. 6Japanese Development and Sales License for NeoCart3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Medinet yet. It last moved in the Earnings of 2026-08-13: "Achieved".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.